Hyperbaric oxygen therapy improves the efficacy of conventional supportive treatment for late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation

This study aims to investigate the efficacy and safety of hyperbaric oxygen therapy (HBOT) in the treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. This retrospective analysis included 16 patients with late-onset hemorrhagic cystitis after allogen...

Full description

Saved in:
Bibliographic Details
Published in:Hematology (Luxembourg) 2024-12, Vol.29 (1), p.2356307-2356307
Main Authors: Qu, Yiwen, Zhao, Peng, Ding, Xiaojie, Qiao, Xiansen, Wang, Ling, Li, Ying
Format: Article
Language:English
Subjects:
Adult
allogeneic hematopoietic stem cell transplantation
Cystitis - etiology
Cystitis - therapy
Cystitis, Hemorrhagic
Female
Hematopoietic Stem Cell Transplantation - adverse effects
Hematuria - etiology
Hematuria - therapy
Hemorrhage - etiology
Hemorrhage - therapy
hemorrhagic cystitis
Humans
Hyperbaric oxygen therapy
Hyperbaric Oxygenation
Male
Middle Aged
Retrospective Studies
Transplantation, Homologous
Treatment Outcome
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aims to investigate the efficacy and safety of hyperbaric oxygen therapy (HBOT) in the treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. This retrospective analysis included 16 patients with late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation between 2016 and 2022. Among them, 8 patients received HBOT in addition to conventional treatment, while the other 8 received only conventional treatment. The clinical efficacy and safety of HBOT were evaluated by comparing the Numeric Rating Scale pain scores and clinical grades of hematuria before and after treatment, reflecting the patients' urinary pain and hematuria status. The patients were divided into two groups based on whether they received HBOT. The group that received HBOT (  = 8) had a shorter duration of illness compared to the non-HBOT group (  = 8) (  
ISSN:1607-8454
1607-8454
DOI:10.1080/16078454.2024.2356307